AMBI I has gotten remarkably cheap. Are you still following it?
Yes, AMBI very much on my watch list for potential future consideration. Clearly, the lead value-driver is quizartinib. Although it's in a Phase 3 and you know I hate to bet on Phase 3 binary events, which I usually view as a crapshoot regardless of prior data, I don't think the data is due until at least 2H15. So, there is potential to get in and be able to hold for awhile and hope for a bounce before the pivotal data. Also, they have a pipeline beyond quizartinib, including a drug targeting CSF1R, which I would like to see more data on. Finally, they have a nice cash position to go along with what seems like a cheap valuation.
BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands.
“The addition of Roche, a global leader and innovator, to our family of collaborators underscores BIND’s unique, leading position in the field of nanomedicine,,” said Scott Minick, Chief Executive Officer of BIND Therapeutics. “By combining BIND’s Medicinal Nanoengineering® platform with Roche’s deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas.”
Market Data 
Markets 
AI
